# Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy

> **NCT00004249** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** QS21
- **BIOLOGICAL:** keyhole limpet hemocyanin
- **DRUG:** polysialic acid

## Key facts

- **NCT ID:** NCT00004249
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** 2001-11
- **Final completion:** 2001-11
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004249, "Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00004249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*